...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of infectious diseases : >Use of the FebriDx point-of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection during the second (COVID-19) wave in Italy
【24h】

Use of the FebriDx point-of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection during the second (COVID-19) wave in Italy

机译：在意大利的第二（Covid-19）波中，在意大利的第二（Covid-19）波中，FEBRIDX护理试验中排除SARS-COV-2诊断的诊断

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective Evaluate the real-world accuracy of Myxovirus resistance protein A (MxA) detected by the rapid, point-of-care FebriDx test during the second-wave pandemic in Italy in patients with acute respiratory infection (ARI) and a clinical suspicion of COVID-19. Design and methods Prospective, observational, diagnostic accuracy study whereby hospitalized patients with ARI were consecutively enrolled in a single tertiary care center in Italy from August 1, 2020 to January 31, 2021. Results COVID-19 was diagnosed in 136/200 (68.0%) patients and Non-COVID-19 was diagnosed in 64/200 (32.0%) patients. COVID-19 patients were younger and had a lower Charlson comorbidity index compared to Non-COVID-19 patients (p 0.001). Concordance between FebriDx, MxA and rt-PCR for SARS-CoV-2 (gold standard) was good (k 0.93, 95% CI 0.87–0.99). Overall sensitivity and specificity were 97.8% [95% CI 93.7–99.5] and 95.3% [95% CI 86.9%–99.0%], respectively. FebriDx demonstrated a negative predictive value of 95.3% (95% CI 86.9–99.0) for an observed disease prevalence of 68%. Conclusions FebriDx MxA showed high diagnostic accuracy to identify COVID-19 and could be considered as a real-time triage tool to streamline the management of suspected COVID-19 patients. FebriDx also detected bacterial etiology in Non-COVID-19 patients suggesting good performance to distinguish bacterial from viral respiratory infection.
机译：目的评价在急性呼吸道感染（ARI）患者的急性呼吸道患者中，在意大利的第二波大流行病中检测到肌瘤病毒抗性蛋白A（MXA）的真实准确性，急性呼吸道感染（ARI）和Covid的临床怀疑-19。设计和方法预期，观察，诊断准确性研究，从2020年8月1日至1月31日，在意大利的一级高等教育中心入院患者入住的ARI患者。结果Covid-19于136/200（68.0％）诊断）患者和非Covid-19被诊断为64/200（32.0％）患者。 Covid-19患者较年轻，与非Covid-19患者相比，Charlson合并症指数较低（P <0.001）。用于SARS-COV-2（金标准）的FEBRIDX，MXA和RT-PCR之间的一致性（K 0.93,95％CI 0.87-0.99）。整体敏感性和特异性分别为97.8％[95％CI 93.7-99.5]和95.3％[95％CI 86.9％-99.0％]。 Febridx显示出95.3％（95％CI 86.9-99.0）的负面预测值，观察到的疾病患病率为68％。结论FeBridx MXA表现出高诊断准确性，以识别Covid-19，可以被视为用于简化疑似Covid-19患者的管理的实时分类工具。 FeBridx还发现非Covid-19患者的细菌病因，表明从病毒呼吸道感染区分细菌性能的良好性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号